Generate Biomedicines grants 190,034 options to CLO

Generate Biomedicines, Inc. reported that Chief Legal Officer & General Counsel Martin Sean received a grant of stock options covering 190,034 shares on February 26, 2026.

Accepted by SEC EDGAR 03/02/2026 - 05:58 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Generate Biomedicines, Inc. reported that Chief Legal Officer & General Counsel Martin Sean received a grant of stock options covering 190,034 shares on February 26, 2026. The award was recorded as a grant or other acquisition, not an open-market purchase. According to the disclosure, the options vest in 48 equal monthly installments starting after February 19, 2026, and each installment requires his continued service on the relevant vesting date.

Insider Trade Summary

Grant/Award: 190,034 shares

Grant/Award 1 txn

Insider Martin Sean

Role Chief Legal Officer & GC

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	190,034	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 190,034 contracts (Direct)

Holdings Before and After: Stock Option (Right to Buy), 0 to 190,034 contracts (Direct)

Footnotes (1)

1. F1. The shares underlying this option shall vest in forty-eight equal monthly installments following February 19, 2026, subject to the Reporting Person's continued service on each such vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Generate Biomedicines (GENB) report for Martin Sean?

Generate Biomedicines reported a stock option grant to Chief Legal Officer & General Counsel Martin Sean. He received options covering 190,034 shares, classified as a grant or award acquisition rather than an open-market buy or sell transaction.

How many stock options did Martin Sean receive from Generate Biomedicines (GENB)?

Martin Sean received a stock option covering 190,034 shares of Generate Biomedicines common stock. This entire amount was reported as acquired in a single grant transaction dated February 26, 2026, with 190,034 derivative securities held directly afterward.

What is the vesting schedule for Martin Sean’s Generate Biomedicines (GENB) stock options?

The options vest in forty-eight equal monthly installments following February 19, 2026. Each monthly vesting installment is conditioned on Martin Sean’s continued service with Generate Biomedicines on the relevant vesting date, spreading the benefit over a four-year period.

Was Martin Sean’s Generate Biomedicines (GENB) option grant an open-market purchase?

No, the transaction was classified as a grant, award, or other acquisition, not an open-market purchase. The Form 4 identifies the code as “A” and describes the action as a grant or award acquisition of stock options rather than a market trade.

Does Martin Sean hold the Generate Biomedicines (GENB) options directly or indirectly?

The disclosure states that Martin Sean holds the 190,034 stock options directly. The ownership is coded as direct, with no footnote indicating that the options are held through a trust, partnership, or other related entity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Martin Sean

(Last) (First) (Middle)

GENERATE BIOMEDICINES, INC.

101 SOUTH STREET, SUITE 900

(Street)

SOMERVILLE MA 02143

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Generate Biomedicines, Inc. [ GENB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer & GC

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$16	02/26/2026		A		190,034		(1)	02/25/2036	Common Stock	190,034	$0	190,034	D

Explanation of Responses:

1. The shares underlying this option shall vest in forty-eight equal monthly installments following February 19, 2026, subject to the Reporting Person's continued service on each such vesting date.

	/s/ Michael Wolf, Attorney-in-Fact	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.